Fatma Nalan Cetin

Fatma Nalan Cetin

Auto-generated profile, based on publicly available information

Fatma Nalan Cetin

Polymer Chemistry and Biomaterials Group Centre of Macromolecular Chemistry Department of Organic and Macromolecular Chemistry Ghent University Ghent Belgium

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2024 in Advanced Healthcare Materials
Verified
Journal Article
Closed access
FCFatma N. Cetin
Fatma N. Cetin
AMArn Mignon
Arn Mignon
Sandra Van VlierbergheSandra Van Vlierberghe
Sandra Van Vlierberghe
Kristyna KolouchovaKristyna Kolouchova
Kristyna Kolouchova

13 September 2026 in Advanced Healthcare Materials
Verified
Journal Article
Open access
PDF file
OGOndrej Groborz
Ondrej Groborz
VHVít Herynek
Vít Herynek
MHMária Hovořáková
Mária Hovořáková
ZPZuzana Pavlíková
Zuzana Pavlíková
LDLinda Dalecká
Linda Dalecká
Kristyna KolouchovaKristyna Kolouchova
Kristyna Kolouchova
Gastrointestinal (GI) transit shapes nutrient absorption and oral drug delivery. However, GI anatomy, function, and motility disorders are primarily examined by radiographic imaging, which exposes patients to ionizing radiation and yields only coarse proxies of how a meal moves through the gut. By contrast, fluorine‐19 ( 19 F) MRI offers background‐free, quantitative tracking, but most oral 19 F agents are hydrophobic and phase‐separate from chyme, generating layering artifacts, which spoil motility and anatomy readouts. Here, we developed nonresorbable, hydrophilic fluorinated polymer tracers miscible with luminal contents. These tracers provided a strong, quantifiable 19 F signal for combined 1 H/ 19 F MRI and 19 F spectroscopy, enabling us to visualize GI anatomy and transit noninvasively. In vivo imaging reliably tracked whole‐gut transit and fecal elimination, with no evidence of systemic uptake or tissue injury. As such, this practical, reproducible, and radiation‐free platform for phenotyping dysmotility and monitoring therapeutic response may open up opportunities for longitudinal GI studies and clinical trials.